AstraZeneca Pharma India Limited (NSE: ASTRAZEN) submitted its financial results for the quarter ended June 30, 2026 to the NSE on August 10, 2026, continuing a pattern of regular quarterly disclosures. The announcement follows the company's most recent dividend declaration in May 2025, when its board recommended a final dividend of ₹32 per equity share for FY25, underscoring a sharply accelerating shareholder return trajectory over the past four fiscal years.
Dividend Details and Year-on-Year Comparison
The FY25 final dividend of ₹32 per share represents a 33.3% increase over the FY24 payout of ₹24 per share, which itself was 50% higher than the FY23 dividend of ₹16 per share. In FY22, the company paid ₹8 per share as a final dividend. This progression, ₹8 in FY22, ₹16 in FY23, ₹24 in FY24, and ₹32 in FY25, reflects a compounded annual growth rate of approximately 58.7% in dividend per share over three years, a notably consistent doubling pattern that has now moderated into steady incremental growth.
Dividend Yield Context
With market price data unavailable in the current feed, a precise dividend yield cannot be calculated at this time. Investors should compute yield as ₹32 divided by the prevailing market price to assess income return relative to the current trading level. Given that ASTRAZEN is a mid-to-large cap pharmaceutical listing, the absolute payout of ₹32 per share on a face value of ₹2 per share represents a payout that is 16 times the face value, reflecting strong underlying cash generation.
Long-Term Dividend History and Trend Analysis
A review of the complete dividend history reveals several distinct phases in AstraZeneca Pharma India's payout policy:
- 2009 to 2011: Payouts ranged from ₹10 to ₹15 per share, reflecting an earlier period of relative generosity when the company operated on a different financial year cycle.
- 2012: The dividend fell sharply to ₹3.50 per share, signalling a period of earnings pressure or reinvestment priority.
- 2019 to 2021: Interim dividends of ₹1 and ₹2 per share indicated a conservative capital return phase, likely aligned with global parent AstraZeneca PLC's strategic priorities during the pandemic period.
- 2022 to 2025: A decisive reversal began with ₹8 in FY22, scaling fourfold to ₹32 in FY25, suggesting sustained improvement in domestic profitability and free cash flow.
Company Background
AstraZeneca Pharma India Limited is a subsidiary of the global biopharmaceutical major AstraZeneca PLC, listed on the NSE with ISIN INE203A01020. The company operates in the prescription pharmaceutical segment in India, with a portfolio spanning oncology, cardiovascular, respiratory, and rare disease therapeutics. Its Indian operations have benefited from increased adoption of specialty medicines and expanding insurance coverage across urban and semi-urban markets.
What This Means for Investors
The Q1 FY27 results filing on August 10, 2026 will be closely watched by the market for evidence that the earnings trajectory supporting the four-year dividend growth trend remains intact. The consistent year-on-year increase in absolute dividend per share, without any bonus issue or stock split dilution in recent years, points to genuine earnings-per-share expansion at the operating level. Investors tracking the stock should note that the delivery percentage data for recent sessions was unavailable in the current feed, which limits the ability to assess institutional conviction through volume quality metrics at this time. The 52-week range context similarly awaits updated market data. The next key event will be the board's dividend recommendation for FY26, expected around May 2026, where the market will assess whether the ₹8-per-year increment is sustained or accelerated.